The Technology Corner: 3 Companies That Could Eradicate Ebola Virus
Written on Apr 24, 2012
To the scientific community, the Ebola virus is one of the most noxious pathogens identified to date. To the general population, the virus is dreadful, made especially frightening in pop culture.
In addition to a high mortality rate of approximately 70 percent per case (average)1, the health deterioration...
Editor’s Note April 24, 2012
Written on Apr 24, 2012
This week, OneMedPlace is pleased to announce a special interview series exploring current issues facing the diagnostics sector and life sciences with Dr. Shi of EdgeTech Law.
In addition, we bring you three management interviews with emerging companies. Biovest CEO and Sr. Vice President discuss global...
Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream
Written on Apr 24, 2012
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity. Dr. Shi is optimistic that genome sequencing can become an affordable and intriguing choice for patients and curious individuals, however she identifies the potential...
Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad
Written on Apr 20, 2012
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise. Dr. Shi offers musings on the unique behavior of diagnostics, as well as how drug development has responded to social...
Dr. Shi of EdgeTech Law: Despite Mayo Clinic v. Prometheus “Setback,” Opportunities in Life Sciences Remain
Written on Apr 19, 2012
OneMedPlace is pleased to announce a special interview series exploring current issues facing the diagnostics sector and life sciences in general with Dr. Qin Shi, Managing Principal of Edgetech Law.
The series features segments of a Q&A session covering many aspects of the sector, from intellectual...
Biovest CEO and Sr. Vice President Discuss Global Marketing of BiovaxID
Written on Apr 19, 2012
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), recently announced that the company is seeking marketing approval in Canada for BiovaxID®, its personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma, an...
